Drug intelligence / Profile preview

GBS101

Development stage: Preclinical
Lead developer: Gb Sciences
Modality: Small Molecules
Administration: Oral

Overview

**GBS101** is a proprietary, cannabinoid- and terpenoid-containing complex active pharmaceutical ingredient developed by GB Sciences as an oral treatment candidate for Parkinson's disease. It is one of three related Parkinson's disease candidates evaluated for formulation using Catalent's Zydis orally disintegrating tablet technology. Public materials describe the candidate class as synergistic complex mixtures containing up to nine individual components, but do not disclose GBS101's exact composition, molecular targets, or a target-specific mechanism of action. ([catalent.com](https://www.catalent.com/news/catalent-selected-to-provide-oral-delivery-systems-for-gb-sciences-proprietary-parkinson-s-disease-therapies))

Beyond the preview

Go deeper on GBS101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBS101.

Explore the full profile